Wedbush Equities Analysts Reduce Earnings Estimates for SWTX

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) – Equities researchers at Wedbush reduced their FY2027 EPS estimates for SpringWorks Therapeutics in a research report issued on Monday, January 13th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of $3.42 per share for the year, down from their prior forecast of $3.47. Wedbush currently has a “Outperform” rating and a $77.00 price target on the stock. The consensus estimate for SpringWorks Therapeutics’ current full-year earnings is ($3.12) per share.

SpringWorks Therapeutics (NASDAQ:SWTX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.03. SpringWorks Therapeutics had a negative return on equity of 48.21% and a negative net margin of 203.09%. The company had revenue of $49.10 million during the quarter, compared to the consensus estimate of $53.28 million. During the same period in the prior year, the company earned ($1.27) earnings per share. The company’s revenue for the quarter was up 4810.0% compared to the same quarter last year.

Several other research analysts have also recently weighed in on the company. Evercore ISI assumed coverage on SpringWorks Therapeutics in a research report on Wednesday, November 20th. They set an “outperform” rating and a $60.00 price objective for the company. HC Wainwright decreased their price target on shares of SpringWorks Therapeutics from $76.00 to $74.00 and set a “buy” rating for the company in a research note on Tuesday, November 12th. Finally, Guggenheim reduced their price target on SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $70.00.

SpringWorks Therapeutics Trading Down 12.2 %

Shares of NASDAQ SWTX opened at $32.50 on Wednesday. The company has a fifty day moving average price of $37.97 and a 200 day moving average price of $36.40. SpringWorks Therapeutics has a 1-year low of $28.21 and a 1-year high of $53.92. The firm has a market cap of $2.42 billion, a PE ratio of -8.38 and a beta of 0.82.

Insider Buying and Selling

In other news, COO Badreddin Edris sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $41.97, for a total value of $839,400.00. Following the completion of the sale, the chief operating officer now directly owns 209,600 shares of the company’s stock, valued at $8,796,912. This trade represents a 8.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 7.61% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Alpha DNA Investment Management LLC bought a new position in SpringWorks Therapeutics during the third quarter worth $411,000. D. E. Shaw & Co. Inc. boosted its holdings in shares of SpringWorks Therapeutics by 16.9% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 758,712 shares of the company’s stock worth $28,581,000 after buying an additional 109,865 shares during the period. Ally Bridge Group NY LLC bought a new position in SpringWorks Therapeutics in the 3rd quarter valued at about $7,296,000. Los Angeles Capital Management LLC lifted its position in SpringWorks Therapeutics by 238.3% during the third quarter. Los Angeles Capital Management LLC now owns 47,212 shares of the company’s stock worth $1,513,000 after acquiring an additional 33,255 shares during the last quarter. Finally, Seven Eight Capital LP acquired a new position in shares of SpringWorks Therapeutics in the second quarter valued at approximately $1,854,000.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.